Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PTC THERAPEUTICS, INC.

(PTCT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PTC Therapeutics' : Tegsedi Receives Innovative Drug Category Pricing in Brazil; Shares Rise Early

10/11/2021 | 09:54am EST


ę MT Newswires 2021
All news about PTC THERAPEUTICS, INC.
12/03PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
12/02PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
11/30PTC THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form..
AQ
11/16PTC Therapeutics to Participate at Upcoming Virtual Investor Conference
PR
10/29Raymond James Adjusts Price Target on PTC Therapeutics to $55 from $70, Keeps Outperfor..
MT
10/29Credit Suisse Lowers PTC Therapeutics' PT to $48 from $50, Keeps Neutral Rating
MT
10/29RBC Capital Trims Price Target on PTC Therapeutics to $42 From $45, Keeps Sector Perfor..
MT
10/28Q3 2021 fls
PU
10/28PTC THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and..
AQ
10/28PTC Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months E..
CI
More news
Analyst Recommendations on PTC THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 508 M - -
Net income 2021 -513 M - -
Net cash 2021 485 M - -
P/E ratio 2021 -5,21x
Yield 2021 -
Capitalization 2 500 M 2 500 M -
EV / Sales 2021 3,97x
EV / Sales 2022 3,25x
Nbr of Employees 963
Free-Float 97,0%
Chart PTC THERAPEUTICS, INC.
Duration : Period :
PTC Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PTC THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 35,36 $
Average target price 51,30 $
Spread / Average Target 45,1%
EPS Revisions
Managers and Directors
Stuart Walter Peltz Chief Executive Officer & Director
Emily Hill Chief Financial Officer
Michael Schmertzler Chairman
Neil Gregory Almstead Chief Technical Operations Officer
Mark Jerome Pykett Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
PTC THERAPEUTICS, INC.-41.13%2 500
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.23%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819